BEGEV Salvage Regimen Linked to High Complete Remission Rates
5-year results from that a study on BEGV have confirmed its benefits in classical Hodgkin lymphoma.
Lymphoma
LYMPHOMA ADVISOR
FEATURED CONTENT
-
-
Current and Prospective Treatment Options for Waldenström Macroglobulinemia
Researchers discussed diagnostic considerations, indications for therapy, and treatment options for patients with Waldenström macroglobulinemia. -
CAR-T Therapy: Supporting Evidence and Value Considerations
Although CAR-T therapies have shown favorable response rates, they can be incredibly costly and may not be priced in alignment with their benefits. -
Immunoglobulin Replacement May Benefit Some Patients Receiving CAR-T Therapy
CAR-T therapy can sometimes lead to immune system dysfunction, subsequent hypogammaglobulinemia, and the need for antibody replacement therapy. -
Mass Cytometry for Profiling the Classic Hodgkin Lymphoma Microenvironment
The technique allows researchers to detect various subpopulations of immune cells by simultaneous interrogation of dozens of proteins.
VIDEO SERIES
LYMPHOMA NEWS
Best Practices for Diagnosing Breast Implant-Associated Anaplastic Large Cell Lymphoma
Priority Review Granted to Tazemetostat for Follicular Lymphoma Indication
Comparing Cost-Effectiveness of First-Line Treatment Approaches for Hodgkin Lymphoma
Prognostic Factors for Patients Undergoing Autologous Stem Cell Transplant for DLBCL
Molecular Targets Identified for Rare Type of Breast Implant–Associated Lymphoma
Want to read more?
Please login or register first to view this content.
Next post in Lymphoma
